Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$538.02 USD

538.02
56,531

-1.98 (-0.37%)

Updated Jul 5, 2024 04:00 PM ET

After-Market: $538.00 -0.02 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 249)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Up 4.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DVA vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Now Trades Above Golden Cross: Time to Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SMMV

Chemed's (CHE) VITAS Performance Aids, Macro Issues Linger

by Zacks Equity Research

Chemed (CHE) believes Roto-Rooter is well-positioned for growth and anticipates continued expansion of the segment's market share.

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Q3 Earnings and Revenues Surpass, Margins Rise

by Zacks Equity Research

Chemed's (CHE) third-quarter 2023 performance reflects strength in the VITAS segment.

Chemed (CHE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Chemed (CHE) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Chemed (CHE) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 8.13% and 0.79%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Acquires Majority Stake in Shield Healthcare

by Zacks Equity Research

Henry Schein (HSIC) completes the majority investment in Shield Healthcare, Inc.

OPCH or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

DVA vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Faces Macroeconomic Woes, Tough Competition

by Zacks Equity Research

Inflationary trend, increased logistics costs and higher employee-related expenses continue to hurt Chemed's (CHE) growth.

OPCH vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

OPCH vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Q2 Earnings Miss Estimates, '23 EPS View Down

by Zacks Equity Research

Chemed's (CHE) second-quarter 2023 performance reflects strength in the VITAS segment, while expenses weigh on margins.

Chemed (CHE) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Chemed (CHE) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Chemed (CHE) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of -7.47% and 1.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

DVA vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.

Debanjana Dey headshot

4 Stocks to Hold in a Challenging Outpatient Home Health Industry

by Debanjana Dey

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE, AMED and ADUS are well poised to gain.

Strength Seen in Amedisys (AMED): Can Its 15.4% Jump Turn into More Strength?

by Zacks Equity Research

Amedisys (AMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.